Is CBD (cannabidiol) legal in the UK, and are edibles legal?

CBD is legal in the UK as a food supplement under the FSA Novel Foods regime, provided it contains no more than trace THC — 'is cannabidiol legal in the UK' and 'are edibles legal in the UK' are among the market's most-searched questions (~650 and ~520/month). THC edibles and recreational cannabis remain illegal, which is why recreational demand is just 4% of the UK market vs 26% in the US. Newer cannabinoids (HHC, delta-8) sit in a legal grey zone the searches actively probe.

Do THC drinks get you high?

Yes — and it is a fast-rising question (~2,340 monthly searches, the corpus's second-most-searched after 'what is CBD'), tracking the emergence of THC-infused beverages in US legal markets. In the UK, compliant CBD drinks contain only trace THC and are non-intoxicating; the search interest reflects US product news crossing into UK feeds — a good example of why demand is per-country but the evidence conversation is shared.

How does the UK cannabis market differ from the US?

Measured on identical instruments: UK demand splits medical 49% / wellness 47% / recreational 4% — the US splits wellness 53% / recreational 26% / medical 21%. The UK's lead use-case is epilepsy (via the licensed medicine Epidyolex) and access runs through private clinics; the US's lead use-case is sleep (1.1M searches/month) and access is navigated through dispensaries, state law and medical cards.

Can a cannabis brand run the same content strategy in the UK and US?

Not wholesale. The category and evidence base are shared, but the buying problem differs: UK pages must answer legality, clinic access and product safety under FSA Novel Foods; US pages must answer state law, dispensary choice and product selection. The shared, citable core is the medical evidence — epilepsy, MS spasticity, chemo nausea — which serves both markets.

Why does the UK have almost no recreational cannabis search demand?

Because THC remains illegal recreationally in the UK, recreational queries are just 4% of framed demand (vs 26% in the US, where most states have legal adult use). UK demand concentrates in legal channels: CBD wellness products and the private medical route.

UK vs US — same category, different buying problem

Everything in this study was measured with the same instruments in both countries — which is what makes the contrast decisive rather than anecdotal.

The contrast in one table

Dimension	UK	US
Legal frame	CBD wellness legal (FSA Novel Foods); THC illegal recreationally; medical via private clinics	Recreational + medical legal state-by-state; federally grey
Demand mix	Medical 49% / Wellness 47% / Rec 4%	Wellness 53% / Rec 26% / Medical 21%
Lead use-case	Epilepsy (143K/mo — Epidyolex)	Sleep (1.1M/mo)
Lead forms	Creams 272K · drinks 89K	Pet 192K · oils 92K (+ dispensary flower/vape)
Commercial actors	H&B + CBD brands + private clinics	Dispensary-tech (Leafly, Weedmaps) + brands
Consumer question	"Is it legal — and will it help me?"	"Where and how do I buy?"
Category trajectory	Smaller, gently rising	58M→79M searches/yr, then plateau

What the divergence means

The category is the same; the buying problem is not. UK buyers need reassurance and access — legality, safety, clinic routes. US buyers need navigation and selection — state rules, dispensary choice, product comparison. Content, SEO and AI-answer strategy must localise to the buying problem, not just the spelling.

What is genuinely shared is the evidence core: the licensed indications (epilepsy, MS spasticity, chemo nausea), the safety and quality-assurance story, and the sleep/anxiety/pain testimony base. That shared core is the citable substance both markets' AI answers are starved of.

The GEO angle, measured: in both countries regulators and health-information sites dominate AI-answer citations while commercial brands largely vanish — the same reshuffle we measured in the UK weight-loss market. Building referenced, indication-aware authority content is the whitespace on both sides of the Atlantic; measuring your citation share monthly is how you know it is working.

Every claim on these pages traces to the corpus — 155,012 evidence snippets, 87-month demand series, 4,940 AI citations. Test that claim yourself: ask the cannabis study chatbot.

UK vs US — same category, different buying problem

The contrast in one table

What the divergence means

See this for your own market.